ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Considerations for vaccine efficacy trials targeting emerging infectious diseases
Shelley McLendon outlines what lessons must be learned to prevent future other emerging infectious diseases developing on a similar scale.
Injection Devices: Three Trends Influencing Development & Delivery
"Injection Devices: Three Trends Influencing Development & Delivery” featuring ICON’s Devin Ridgely.
Elite stock: ICON sails through trials with top manager
CFO Brendan Brennan outlines what will drive growth at ICON in his interview with Citywire.
Supporting reimbursement decisions with data from external control arms
In this article ICON experts weigh in on maximising the efficacy of data and ensuring the scientific rigour HTAs expect.
Pharmacovigilance outsourcing: Ensuring a positive experience
Karen Johnstone and Sabine Richter discuss current outsourcing practices and tips for selecting a service provider to ensure a successful relationship.
Longitudinal qualitative research - Capturing the patient voice; enhancing patient centricity
Outcomes researchers Alexia Marrel and Sally Lanar share insights on longitudinal qualitative research - what it is, when and how it can be used and the key factors for success when using this type of research.
Nominations now open for ‘Company of the Year’ Award 2022
This article features commentary from CEO Steve Cutler about ICON being awarded 2021 Company of the Year.
A blended solution – how midsize pharmaceutical and biotech companies can optimise the delivery of their clinical trials
John Barry, SVP and Chief Strategy Officer of ICON’s Strategic Solutions Division, considers the benefits of a blended model that combines FSP scale and CRO project-based sourcing for mid- size pharmaceutical and biotech companies.
How real world evidence is impacting rare disease drug development
Will Maier, VP of Rare Diseases, shares how a more patient-focused approach to trials is leading to alternatives for randomisation.
Incorporating patient preference vital to study success
Jayne Galinsky, Senior Outcomes Researcher, shares the importance of learning and assessing patient preferences in clinical research.